Stock Track | Genor Biopharma Soars on Licensing Deal for GB261

Stock Track08-05

Shares of Genor Biopharma Holdings Ltd (GENOR-B) surged 11.57% during intraday trading on August 5th, following the company's announcement of a licensing agreement and stock purchase agreement with TRC 2004.

According to the agreement, Genor Biopharma has granted TRC 2004 an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261, which is likely a drug candidate or product in Genor Biopharma's pipeline.

Such licensing deals are often seen as positive catalysts for biotech companies, as they provide additional revenue streams through upfront payments, milestone payments, and royalties on future sales. The agreement with TRC 2004 validates Genor Biopharma's product and pipeline, and investors are likely reacting positively to the potential financial benefits this deal could bring to the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169803980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-05 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169803980","market":"us","top_or_hot":-1,"title":"Stock Track | Genor Biopharma Soars on Licensing Deal for GB261","media":"Stock Track","content":"<p>Shares of Genor Biopharma Holdings Ltd (GENOR-B) surged 11.57% during intraday trading on August 5th, following the company's announcement of a licensing agreement and stock purchase agreement with TRC 2004.</p>\n\n<p>According to the agreement, Genor Biopharma has granted TRC 2004 an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261, which is likely a drug candidate or product in Genor Biopharma's pipeline.</p>\n\n<p>Such licensing deals are often seen as positive catalysts for biotech companies, as they provide additional revenue streams through upfront payments, milestone payments, and royalties on future sales. The agreement with TRC 2004 validates Genor Biopharma's product and pipeline, and investors are likely reacting positively to the potential financial benefits this deal could bring to the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Genor Biopharma Soars on Licensing Deal for GB261</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Genor Biopharma Soars on Licensing Deal for GB261\n</h2>\n\n<h4 class=\"meta\">\n\n2024-08-05 09:34 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Genor Biopharma Holdings Ltd (GENOR-B) surged 11.57% during intraday trading on August 5th, following the company's announcement of a licensing agreement and stock purchase agreement with ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06998","symbol_name":"嘉和生物-B","start_time":0,"source_url":"","article_id":"1169803980","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169803980","pubTimestamp":1722821669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Genor Biopharma Holdings Ltd  surged 11.57% during intraday trading on August 5th, following the company's announcement of a licensing agreement and stock purchase agreement with TRC 2004.According to the agreement, Genor Biopharma has granted TRC 2004 an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261, which is likely a drug candidate or product in Genor Biopharma's pipeline.Such licensing deals are often seen as positive catalysts f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06998":"嘉和生物-B"},"translate_title":"嘉和生物制药(Genor Biopharma)因GB261许可协议而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":1},"content_text":"Shares of Genor Biopharma Holdings Ltd (GENOR-B) surged 11.57% during intraday trading on August 5th, following the company's announcement of a licensing agreement and stock purchase agreement with TRC 2004.\nAccording to the agreement, Genor Biopharma has granted TRC 2004 an exclusive worldwide license to develop, use, manufacture, commercialize and otherwise exploit GB261, which is likely a drug candidate or product in Genor Biopharma's pipeline.\nSuch licensing deals are often seen as positive catalysts for biotech companies, as they provide additional revenue streams through upfront payments, milestone payments, and royalties on future sales. The agreement with TRC 2004 validates Genor Biopharma's product and pipeline, and investors are likely reacting positively to the potential financial benefits this deal could bring to the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169803980"}